PILOT OF BUTHIONINE SULFOXIMINE WITH MELPHALAN IN NEUROBLASTOMA

神经母细胞瘤的治疗失败可能与获得性烷化剂有关 烷化剂的抗药性和抗肿瘤作用可能是 因药物丁硫氨酸耗尽谷胱甘肽(GSH)而增加 亚磺胺(BSO)。这项研究将评估药物动力学和 (BS0)与马法兰联合应用的临床毒性 儿童神经母细胞瘤患者。这项研究的另一个目标 是证明外周血淋巴细胞中GSH耗竭，正常 骨髓中发现的骨髓和神经母细胞瘤细胞。

Treatment failure in neuroblastoma likely involves acquired alkylator resistance and the anti-tumor effect of alkylating agents may be increased by depletion of glutathione (GSH) with the drug buthionine sulfoximine (BSO). This study will evaluate the pharmacokinetics and clinical toxicities of the combination of (BS0) and melphalan in pediatric patients with neuroblastoma. An additional goal of this study is to document GSH depletion in peripheral blood lymphocytes, normal marrow and neuroblastoma cells found in the bone marrow.